Freedom of Information Request: 0655 2019/20
University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.
Queen Elizabeth Hospital Birmingham:
- How many patients with cutaneous squamous cell carcinoma have you treated [eg surgery, chemotherapy or radiotherapy] in the past 3 months?
382
- How many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma have you treated [eg surgery, chemotherapy or radiotherapy] in the past 3 months?
34
- Of these how many are not candidates for curative surgery or curative radiation?
We do not hold this information
- In the past 3 months, how many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation have you treated with the following;
Libtayo (cemiplimab) 0
Non curative surgery only 0
Non curative surgery + chemotherapy* 0
Non curative surgery + radiotherapy 0
Non curative surgery + chemotherapy* + radiotherapy 0
Chemotherapy* only 24
Chemotherapy* + radiotherapy 0
Non curative radiotherapy only 0
No treatment 0
Palliative Care / Best Supportive care 0
Other [please state]
*chemotherapy such as cisplatin, doxorubicin, 5-fluorouracil (5-FU), capecitabine, topotecan, or etoposide
- Does your trust treat adult multiple myeloma [MM]?
Yes
– if you refer your multiple myeloma patients to another centre, please state which.
N/A
- If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
Bortezomib [Velcade] 9
Carfilzomib [Kyprolis] 0
Ixazomib [Ninlaro] 1
Lenalidomide [Revlimid] 11
Daratumumab [Darzalex] 7
Melphalan, prednisolone and thalidomide (known as MPT) 0
Cyclophosphamide, thalidomide and dexamethasone (known as CTD) 1
Pomalidomide [Imnovid] 4
- Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible how many CLL patients treated were new to therapy in the past 3 months?
We do not hold this information
- How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR) 1
Bendamustine and rituximab (known as BR) 0
Ibrutinib [Imbruvica] 4
Chlorambucil 0
Venetoclax 2
Obinutuzumab 0
Idelalisib 0
Fludarabine and rituximab (known as FR) 1
High-dose prednisone and rituximab 0
Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) 0
Alemtuzumab (Campath) with rituximab 0
Heartlands, Good Hope and Solihull Hospitals:
- How many patients with cutaneous squamous cell carcinoma have you treated [eg surgery, chemotherapy or radiotherapy] in the past 3 months?
- How many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma have you treated [eg surgery, chemotherapy or radiotherapy] in the past 3 months?
- Of these how many are not candidates for curative surgery or curative radiation?
- In the past 3 months, how many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation have you treated with the following;
Libtayo (cemiplimab)
Non curative surgery only
Non curative surgery + chemotherapy*
Non curative surgery + radiotherapy
Non curative surgery + chemotherapy* + radiotherapy
Chemotherapy* only
Chemotherapy* + radiotherapy
Non curative radiotherapy only
No treatment
Palliative Care / Best Supportive care
Other [please state]
*chemotherapy such as cisplatin, doxorubicin, 5-fluorouracil (5-FU), capecitabine, topotecan, or etoposide
Due to historical differences in information systems across the two former Trusts, we do not hold the information requested in questions 1-4 in a format that allows us to provide it for Heartlands, Good Hope or Solihull Hospitals.
- Does your trust treat adult multiple myeloma [MM]?
Yes
– if you refer your multiple myeloma patients to another centre, please state which.
N/A
- If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
Bortezomib [Velcade] 2 (with Daratumumab – 7)
Carfilzomib [Kyprolis] 1
Ixazomib [Ninlaro] 1 (with Lenalidomide – 18)
Lenalidomide [Revlimid] 19 (with Ixazomib – 18)
Daratumumab [Darzalex] 10 (with Bortezomib – 7, Pomalidomide – 1)
Melphalan, prednisolone and thalidomide (known as MPT) 0
Cyclophosphamide, thalidomide and dexamethasone (known as CTD) 1
Pomalidomide [Imnovid] 4
- Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible how many CLL patients treated were new to therapy in the past 3 months?
We do not hold this information
- How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR) 0
Bendamustine and rituximab (known as BR) 0
Ibrutinib [Imbruvica] 6
Chlorambucil 1 (with Obinutuzumab – 1)
Venetoclax 2
Obinutuzumab (with Chlorambucil – 1)
Idelalisib 0
Fludarabine and rituximab (known as FR) 0
High-dose prednisone and rituximab 0
Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) 0
Alemtuzumab (Campath) with rituximab 0
